Moleculin LLC, based in Houston, TX, is a biopharmaceutical company focused on advancing a diverse pipeline of product candidates for the treatment of highly resistant cancers and viruses. Utilizing proprietary technologies and data, Moleculin is dedicated to developing innovative therapies including next-generation anthracyclines, immune transcription modulators, STAT3 inhibitors, and metabolism glycosylation inhibitors.
With a priority development pipeline and a commitment to pioneering better treatments, Moleculin is at the forefront of creating impactful solutions for challenging medical conditions. Through cutting-edge research and a dedication to advancing therapeutic options, the company aims to provide hope for patients facing complex diseases.
Generated from the website